Targovax ASA: “ONCOS-102 sensitizes tumors to other immunotherapies” – Paper published in the latest issue of OncoImmunology

Scientists from Oncos Therapeutics and leading oncology centers in Finland and Germany have published a paper in the latest issue of the journal OncoImmunology (Vol 3, Issue 10, 2014).

The paper – titled “Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization” – is based on Oncos’s recently concluded Phase I clinical study.

The team reports a case of a 68-year-old male with asbestos-related malignant pleural mesothelioma who was treated in the study with a granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing oncolytic adenovirus, Ad5/3-D24-GMCSF (ONCOS-102).

The treatment resulted in prominent infiltration of CD8+ lymphocytes to tumor, marked induction of systemic antitumor CD8+ T-cells and induction of Th1-type polarization in the tumor. These results indicate that ONCOS-102 treatment sensitizes tumors to other immunotherapies by inducing a T-cell positive phenotype to an initially T-cell negative tumor.

Here is a link to the complete paper.